Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | PRMT5 | O14744 | 12/20 | 0.53 |
| ▸ | WDR77 | Q9BQA1 | 11/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5479006 | 0.88 | RAB9A (0.52) | RAB9ALMNANPC1HTTSMN1; SMN2 | |
| SCHEMBL5472719 | 0.88 | PRMT5 (0.54) | RAB9ALMNANPC1HTTSMN1; SMN2 | |
| SCHEMBL5477242 | 0.86 | RAB9A (0.73) | RAB9ALMNANPC1HTTSMN1; SMN2 | |
| SCHEMBL5489719 | 0.81 | MAPT (0.48) | RAB9ALMNANPC1HTTSMN1; SMN2 | |
| SCHEMBL5481486 | 0.81 | LMNA (0.53) | RAB9ALMNANPC1HTTSMN1; SMN2 | |
| SCHEMBL6475746 | 0.78 | SMN1; SMN2 (0.51) | RAB9ALMNANPC1HTTSMN1; SMN2 | |
| SCHEMBL6475945 | 0.77 | ATP4A (0.56) | RAB9ALMNANPC1HTTSMN1; SMN2 | |
| SCHEMBL15693654 | 0.77 | SMN1; SMN2 (0.69) | RAB9ALMNANPC1HTTSMN1; SMN2 | |
| SCHEMBL6480697 | 0.77 | RAB9A (0.63) | RAB9ALMNANPC1HTTSMN1; SMN2 | |
| SCHEMBL5472730 | 0.77 | MAPT (0.45) | RAB9ALMNANPC1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275995-A1 | Thiobenzimidazole derivatives | TEIJIN PHARMA LIMITED | 2007-11-29 | — | — | US | disclosed |
| US-7268145-B2 | Thiobenzimidazole derivatives | TEIJIN PHARMA LIMITED (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20060040976-A1 | Thiobenzimidazole derivatives | TEIJIN LIMITED | 2006-02-23 | — | — | US | disclosed |
| US-20050267148-A1 | Benzimidazole derivative | TEIJIN LIMITED | 2005-12-01 | — | — | US | disclosed |
| EP-1097926-A1 | THIOBENZIMIDAZOLE DERIVATIVES | TEIJIN LIMITED (JP) | 2001-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275995-A1 | Thiobenzimidazole derivatives | CMA1, SERPINB1, TMPRSS15 | RAB9A 2783/4885LMNA 4278/4885NPC1 525/4885 |
| US-20060040976-A1 | Thiobenzimidazole derivatives | CMA1, SERPINB1, TMPRSS15 | RAB9A 2783/4885LMNA 4278/4885NPC1 525/4885 |
| US-20050267148-A1 | Benzimidazole derivative | CMA1, SERPINB1, TPSAB1 | RAB9A 3040/4885LMNA 3900/4885NPC1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.